The role of matrix metalloproteinases in the myocardial remodeling

Cover Page

Abstract


The main structural event in the development of heart failure is the myocardial remodeling. The extracellular matrix, that was knows as, considered an inert framework of cardiomyocytes, plays an important role in cardiac remodeling. The enzyme system, primarily responsible for the degradation of the extracellular matrix, is a matrix metalloproteinases (MMP). This review examines the evidence for the participation of MMP in the myocardial remodeling and recent studies of MMP as prognostic markers. Regulation of induction and/or activation of MMP are potential therapeutic targets.


Full Text

Restricted Access

About the authors

Vladlen V. Bazylev

Federal Center of Cardiovascular Surgery

Email: kanaeva_tatyana@bk.ru

Russian Federation

D. Sci. (Med.)

Tatyana V. Kanaeva

Federal Center of Cardiovascular Surgery

Author for correspondence.
Email: kanaeva_tatyana@bk.ru

Russian Federation

Cand. Sci. (Med.)

References

  1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30–41.
  2. Braunwald E. Heart failure. JACC Heart Fail 2013; 1: 1–20.
  3. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18 (8): 891–975.
  4. ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 2016; 22 (9): 659–69.
  5. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57 (1): 84–95.
  6. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: experimental observations and clinical implications. Circulation 1990; 81 (4): 1161–72.
  7. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35 (3): 569–82.
  8. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999; 42: 27–44.
  9. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000; 18: 435–42.
  10. Coghlan HC, Coghlan L. Cardiac architecture: Gothic versus Romanesque. A cardiologist’s view. Semin Thorac Cardiovasc Surg 2001; 13: 417–30.
  11. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 2000; 35: 569–82.
  12. Jaffe R, Flugelman MY, Halon DA, Lewis BS. Ventricular remodeling: from bedside to molecule. Adv Exp Med Biol 1997; 430: 257–66.
  13. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissur remodeling. FASEB J 1991; 5 (8): 2145–54.
  14. Hideaki H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69 (3): 562–73.
  15. Ikeda U, Shimuda K. Matrix metalloproteinases and coronary artery disease. Clin Cardiol 2003; 26: 55–9.
  16. Hojo Y, Ikeda U, Takahashi M et al. Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J Mol Cell Cardiol 2000; 8 (32): 1459–68.
  17. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324–33.
  18. Lacraz S, Nicod LP, Chicheportiche R et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304–10.
  19. Aimes RT, Quiqley JP. Matrix metalloproteinase-2 is interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995; 270: 5872–6.
  20. Nagase H. Zinc Metalloproteinases in health and disease. London: Taylor and Francis Ltd, 1996; p. 153–8.
  21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827–39.
  22. Wilson EM, Spinale FG. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med 2001; 33: 623–34.
  23. Spinale FG, Wilbur NM. Matrix metalloproteinase therapy in heart failure. Curr Treat Options Cardiovasc Med 2009; 11: 339–46.
  24. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87: 1285–342.
  25. Cheung P-Y, Sawicki G, Wozniak M et al. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000; 15 (101): 1833–9.
  26. Yabluchanskiy A, Li Y, Chilton RJ, Lindsey ML. Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets 2013; 14: 276–86.
  27. Iyer RP, de Castro Bras LE, Jin YF, Lindsey ML. Translating Koch’s postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res 2014; 114: 860–71.
  28. Etoh T, Joffs C, Deschamps AM et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol 2001; 281: H987–94.
  29. Sahul ZH, Mukherjee R, Song J et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 2011; 4: 381–91.
  30. Wilson EM, Moainie SL, Baskin JM et al. Region- and typespecific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003; 107: 2857–63.
  31. Hutchinson KR, Stewart JA Jr, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 2010; 48: 564–9.
  32. Nagatomo Y, Carabello BA, Coker ML et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol 2000; 278: H151–61.
  33. Deten A, Volz HC, Holzl A et al. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol Cell Biochem 2003; 251 (1–2): 127–37.
  34. Mukherjee R, Mingoia JT, Bruce JA et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol 2006; 291 (5): H 2216–28.
  35. Etoh T, Joffs C, Deschamps AM et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol 2001; 281 (3): H 987–94.
  36. Romanic AM, Burns-Kurtis CL, Gout B et al. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 2001; 68 (7): 799–814.
  37. Tao ZY, Cavasin MA, Yang F et al. Temporal changes in matrix metalloproteinase expression and inflammatory response associated with cardiac rupture after myocardial infarction in mice. Life Sci 2004; 74 (12): 1561–72.
  38. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000; 46 (2): 307–15.
  39. Lindsey ML, Escobar GP, Dobrucki LW et al. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol 2006; 290 (1): H232–9.
  40. Zamilpa R, Ibarra J, de Castro Brás LE et al. Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol 2012; 53: 599–608.
  41. Ducharme A, Frantz S, Aikawa M et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000; 106: 55–62.
  42. Sundstrom J, Evans JC, Benjamin EJ et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004; 109: 2850–6.
  43. Van den Borne SW, Cleutjens JP, Hanemaaijer R et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009; 18 (1): 37–43.
  44. Lindsey ML, Zamilpa R. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther 2012; 30: 31–41.
  45. Yan AT, Yan RT, Spinale FG et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006; 12: 514–19.
  46. Tziakas DN, Chalikias GK, Parissis JT et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004; 94: 269–77.
  47. Webb CS, Bonnema DD, Ahmed SH et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006; 114: 1020–7.
  48. Kelly D, Cockerill G, Ng LL et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28: 711–8.
  49. Wagner DR, Delagardelle C, Ernens I et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006; 12: 66–72.
  50. Fertin M, Dubois E, Belliard A et al. Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol 2012; 110: 277–83.
  51. Squire IB, Evans J, Ng LL et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328–33.
  52. Yan AT, Yan RT, Spinale FG et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006; 12: 514–9.
  53. Kameda K, Matsunaga T, Abe N et al. Increased pericardial fluid level of matrix metalloproteinase-9 activity in patients with acute myocardial infarction: possible role in the development of cardiac rupture. Circ J 2006; 70: 673–8.
  54. Lalu MM, Pasini E, Schulze CJ et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005; 26: 27–35.
  55. Joffs C, Gunasinghe HR, Multani MM et al. Cardiopulmonary bypass induces the synthesis and release of matrix metalloproteinases. Ann Thorac Surg 2001; 71: 1518–23.
  56. Lin TC, Li CY, Tsai CS et al. Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg 2005; 100 (6): 1554–60.
  57. Reinhardt D, Sigusch HH, Hensse J et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002; 88 (5): 525–30.
  58. Seeland U, Kouchi I, Zolk O et al. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts. J Mol Cell Cardiol 2002; 34 (2): 151–63.
  59. Fraccarollo D, Bauersachs J, Kellner M et al. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono-versus combination therapy. Cardiovasc Res 2002; 54 (1): 85–94.
  60. Yamamoto D, Takai S, Jin D et al. Molecular mechanism of imidapril for cardiovascular protection via inhibition of MMP-9. J Mol Cell Cardiol 2007; 43 (6): 670–6.
  61. Sawicki G, Menon V, Jugdutt BI. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade. J Card Fail 2004; 10 (5): 442–9.
  62. Deten A, Volz HC, Holzl A et al. Effect of propranolol on cardiac cytokine expression after myocardial infarction in rats. Mol Cell Biochem 2003; 251 (1–2): 127–37.
  63. Death AK, Nakhla S, McGrath KC et al. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J Am Coll Cardiol 2002; 39: 1943–50.
  64. Tyagi SC, Kumar S, Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiol 1997; 29: 391–404.
  65. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on non-traditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679–84.
  66. Eickelberg O, Roth M, Mussmann R et al. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL-6 and NF-KB in primary human vascular smooth muscle cells. Circulation 1999; 99: 2276–82.
  67. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases- 1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003; 23: 769–75.
  68. Webb CS, Bonnema DD, Ahmed SH et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006; 114: 1020–7.
  69. Aikawa M, Rabkin E, Okada Y et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998; 97: 2433–44.
  70. Aikawa M, Rabkin E, Voglic SJ et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998; 83: 1015–26.
  71. Steinmetz EF, Buckley C, Shames ML et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normaland hypercholesterolemic mice. Ann Surg 2005; 241: 92–101.
  72. Koh KK, Son JW, Ahn JY et al. Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: 19–23.
  73. Crisby M, Nordin-Fredriksson G, Shah PK et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926–33.
  74. Jingchao L, Jie H, Hong D et al. Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. Cell Physiol Biochem 2016; 39: 47–60.
  75. King MK, Coker ML, Goldberg A et al. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res 2003; 92 (2): 177–85.
  76. Hudson MP, Armstrong PW, Ruzyllo W et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006; 48 (1): 15–20.
  77. Hudson MP, Armstrong PW, Ruzyllo W et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006; 48 (1): 15–20.
  78. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of 200 mg oral dose of PG-116800 given as the sodium salt (PG-530742) twice daily for 90 days to patients following acute myocardial infarction, with post-treatment follow-up. Investigator’s Regulatory Brochure 2004; 2002135: 8–51.
  79. Villarreal FJ, Griffin M, Omens J et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003; 108 (12): 1487–92.
  80. Brown DL, Desai KK, Vakili BA et al. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004; 24 (4): 733–8.
  81. Villarreal FJ, Griffin M, Omens J et al. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003; 108 (12): 1487–92.
  82. Villarreal F, Omens J, Dillmann W et al. Early degradation and serum appearance of type I collagen fragments after myocardial infarction. J Mol Cell Cardiol 2004; 36 (4): 597–601.
  83. Garcia RA, Go KV, Villarreal FJ. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 2007; 300 (1–2): 159–69.
  84. Cerisano G, Buonamici P, Valenti R et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J 2014; 35 (3): 184–91.
  85. Gu Y, Walker C, Ryan ME et al. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol 2012; 4: 10.
  86. Zhang Y, Gu Y, Lee HM et al. Design, synthesis and biological activity of new polyenolic inhibitors of matrix metalloproteinases: a focus on chemically-modified curcumins. Curr Med Chem 2012; 19: 4348–58.
  87. Johnson JL, Devel L, Czarny B et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2011; 31 (3): 528–35.
  88. Robichaud TK, Steffensen B, Fields GB Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem 2011; 286 (43): 37535–42.

Statistics

Views

Abstract - 12

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies